- Business
- Net Medical Xpress Solutions, Inc. (NMXS) provides telemedicine solutions and diagnostic services to hospitals, nursing homes, specialty hospitals, urgent cares, trauma centers, imaging centers, jails, and outpatient facilities. The company offers a comprehensive Telemed platform featuring customized telemedicine management systems, FDA-cleared image viewers, digital paper development engine, single pane of glass software, integration with approximately 43 hospital EMR systems, and telemedicine video conferencing equipment with USB clinical tools; specialty services including teleneurology, teleneurosurgery, telecardiology, teleorthopedics, telewoundcare, and telenephrology; diagnostic and clinical programs such as teleradiology, virtual specialist consultations for neurologists, psychiatrists, and cardiologists; hardware solutions like Dell OptiPlex all-in-one touch screen computers mounted on medical carts; staffing and recruiting through Net Medical Xpress Staffing; call center operations; and research and development capabilities focused on artificial intelligence software named PrivateAI (Private Eye). Founded in 1995 by Richard F. Govatski and headquartered at 8206 Louisiana Boulevard NE, Suite A, Albuquerque, New Mexico, the company operates primarily in the United States with emphasis on rural and remote medical service areas. Recent developments include a growing strategic partnership with Accorto Regulatory Solutions announced in early 2023 to support clinical trials and FDA approvals for medical devices through participation in events like the Medical Design & Manufacturing trade show; major updates to the Telemed platform in mid-2022 enhancing kiosk software for hospital acute care with improved hardware support, security, customizability, and usability; expansion of mobile on-site CLIA labs and COVID, flu, and RSV PCR testing services in New Mexico in late 2022 amid reduced state funding; launch of the Immunity Science website and online store in early 2023 offering immune-boosting supplements targeting colds, flu, inflammation, and cell mutations; and reported 2022 full-year gross revenue of $5.2 million versus $1.768 million in 2021 with net income of $885,000 versus $10,000, alongside nine-month 2022 revenue of $4.4 million and Q3 net income of $1.3 million.